Transaction DateRecipientSharesTypePriceValue
22nd December 2020Partners L P/Il Bvf97,615Conversion of derivative$0.00
22nd December 2020Partners L P/Il Bvf15,166Conversion of derivative$0.00
22nd December 2020Partners L P/Il Bvf509,410Conversion of derivative$0.00
22nd December 2020Partners L P/Il Bvf1,944Conversion of derivative$0.00
22nd December 2020Partners L P/Il Bvf654,215Conversion of derivative$0.00
22nd December 2020Partners L P/Il Bvf11,278Conversion of derivative$0.00
15th December 2020James R Neal26,000Exercise of derivative$5.50$143,000.00
15th December 2020James R Neal5,706Open or private sale$42.04$239,900.21
15th December 2020James R Neal20,294Open or private sale$41.15$835,098.10
15th December 2020James R Neal8,000Grant/award etc.$25.00$200,000.00
Xoma
Xoma logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.


XOMA Corp. engages in the discovery and development of innovative therapeutics derived from platform of antibody technologies. Its products includes X358, X213, X129, and gevokizumab.


Ticker: XOMA
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 791908
Employees: 10
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Assets, Current: $52 M (-12%)
Property, Plant and Equipment, Net: $22 Th (-35%)
Other Assets, Noncurrent: $215 Th (42%)
Assets: $88 M (-8%)
Long-term Debt, Current Maturities: $8 M (0%)
Accounts Payable, Current: $646 Th (5%)
Liabilities, Current: $11 M (27%)
Long-term Debt, Excluding Current Maturities: $23 M (0%)
Other Liabilities, Noncurrent: $35 Th (-18%)
Liabilities: $49 M (-4%)
Common Stock, Value, Issued: $83 Th (13%)
Common Stock, Shares, Issued: $11 M (12%)
Retained Earnings (Accumulated Deficit): $1 B (0%)
Stockholders' Equity (Parent): $38 M (0%)
Liabilities and Equity: $88 M (-8%)
Revenue: $53 Th (-90%)
Research and Development: $38 Th (-62%)
General and Administrative Expenses: $4 M (-64%)
Operating Income/Loss: $3 M (-64%)
Provision for income taxes: $2 M (1%)